Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessments.
Anabolic treatment
Chronic obstructive pulmonary disease
Exit interviews
Muscle weakness
Patient experience
Performance outcome assessment
Qualitative interview
Trial participation
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
20 Apr 2024
20 Apr 2024
Historique:
received:
16
03
2023
accepted:
10
03
2024
medline:
20
4
2024
pubmed:
20
4
2024
entrez:
19
4
2024
Statut:
epublish
Résumé
Chronic obstructive pulmonary disease (COPD) and muscle weakness can cause impaired physical function, significantly impacting patients' health-related quality of life (HRQoL). Loss of muscle strength is usually assessed through clinical and performance outcome (PerfO) assessments, which consists of tasks performed in a standardized manner, providing evidence of a patient's functional ability. However, evidence documenting the patient experience of COPD and muscle weakness is limited. This two-stage qualitative study used semi-structured interviews in patients aged 45-80 years with COPD (post-bronchodilator forced expiratory volume in 1s [FEV In Stage 1 (n = 20), most participants described their muscles as weak (83.3%). Difficulties with walking (100%) and lifting heavy objects (90%) were reported. In Stage 2, 60-minute interviews, all participants (n = 32) reported a positive trial experience. Most participants reported that the home exercise program was easy to fit into daily life (77.8%), the PROactive daily diary was easy to complete (100%) and wearable sensors were easy to use (65.6%). However, technical issues were reported (71%), and few participants (19.4%) found physical assessments easy to complete. Improvements in muscle strength and functional limitations were reported by most participants. The shorter 15-minute confirmatory interviews (n = 35) supported the in-depth interview results. The qualitative interviews generated in-depth evidence of key concepts relevant to patients with COPD and muscle weakness and support the assessments of patient strength and physical function as outcome measures in this population in future studies. GSK Stage 1: 206869; Stage 2: 200182, NCT03359473; Registered December 2, 2017, https://clinicaltrials.gov/ct2/show/NCT03359473 .
Sections du résumé
BACKGROUND
BACKGROUND
Chronic obstructive pulmonary disease (COPD) and muscle weakness can cause impaired physical function, significantly impacting patients' health-related quality of life (HRQoL). Loss of muscle strength is usually assessed through clinical and performance outcome (PerfO) assessments, which consists of tasks performed in a standardized manner, providing evidence of a patient's functional ability. However, evidence documenting the patient experience of COPD and muscle weakness is limited.
METHODS
METHODS
This two-stage qualitative study used semi-structured interviews in patients aged 45-80 years with COPD (post-bronchodilator forced expiratory volume in 1s [FEV
RESULTS
RESULTS
In Stage 1 (n = 20), most participants described their muscles as weak (83.3%). Difficulties with walking (100%) and lifting heavy objects (90%) were reported. In Stage 2, 60-minute interviews, all participants (n = 32) reported a positive trial experience. Most participants reported that the home exercise program was easy to fit into daily life (77.8%), the PROactive daily diary was easy to complete (100%) and wearable sensors were easy to use (65.6%). However, technical issues were reported (71%), and few participants (19.4%) found physical assessments easy to complete. Improvements in muscle strength and functional limitations were reported by most participants. The shorter 15-minute confirmatory interviews (n = 35) supported the in-depth interview results.
CONCLUSION
CONCLUSIONS
The qualitative interviews generated in-depth evidence of key concepts relevant to patients with COPD and muscle weakness and support the assessments of patient strength and physical function as outcome measures in this population in future studies.
TRIAL NUMBER
BACKGROUND
GSK Stage 1: 206869; Stage 2: 200182, NCT03359473; Registered December 2, 2017, https://clinicaltrials.gov/ct2/show/NCT03359473 .
Identifiants
pubmed: 38641716
doi: 10.1186/s41687-024-00712-0
pii: 10.1186/s41687-024-00712-0
doi:
Banques de données
ClinicalTrials.gov
['NCT03359473']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Subventions
Organisme : GSK
ID : GSK
Informations de copyright
© 2024. The Author(s).
Références
Attaway AH, Welch N, Hatipoğlu U, Zein JG, Dasarathy S (2021) Muscle loss contributes to higher morbidity and mortality in COPD: an analysis of national trends. Respirology 26:62–71. https://doi.org/10.1111/resp.13877
doi: 10.1111/resp.13877
pubmed: 32542761
Global Initiative for Chronic Obstructive Lung Disease (2020) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf . Accessed 16 April 2021
Langer D, Ciavaglia C, Faisal A, Webb KA, Neder JA, Gosselink R, Dacha S, Topalovic M, Ivanova A, O’Donnell DE (2018) Inspiratory muscle training reduces diaphragm activation and dyspnea during exercise in COPD. J Appl Physiol 125:381–392. https://doi.org/10.1152/japplphysiol.01078.2017
doi: 10.1152/japplphysiol.01078.2017
pubmed: 29543134
Jolley CJ, Moxham J (2009) A physiological model of patient-reported breathlessness during daily activities in COPD. Eur Respir Rev 18:66–79. https://doi.org/10.1183/09059180.00000809
doi: 10.1183/09059180.00000809
pubmed: 20956127
Vázquez-Gandullo E, Hidalgo-Molina A, Montoro-Ballesteros F, Morales-González M, Muñoz-Ramírez I, Arnedillo-Muñoz A (2022) Inspiratory Muscle Training in patients with chronic obstructive pulmonary disease (COPD) as part of a respiratory Rehabilitation Program implementation of mechanical devices: a systematic review. Int J Environ Res Public Health 19. https://doi.org/10.3390/ijerph19095564
Von Haehling S, Anker SD (2010) Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 1:1–5. https://doi.org/10.1007/s13539-010-0002-6
doi: 10.1007/s13539-010-0002-6
Von Haehling S, Anker SD (2014) Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014. J Cachexia Sarcopenia Muscle 5:261–263
doi: 10.1007/s13539-014-0164-8
Watz H, Waschki B, Meyer T, Magnussen H (2009) Physical activity in patients with COPD. Eur Respir J 33:262–272. https://doi.org/10.1183/09031936.00024608
doi: 10.1183/09031936.00024608
pubmed: 19010994
Liu CJ, Latham NK (2009) Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002759.pub2
doi: 10.1002/14651858.CD002759.pub2
pubmed: 19821382
pmcid: 4324332
Saeterbakken AH, Bardstu HB, Brudeseth A, Andersen V (2018) Effects of Strength Training on muscle properties, physical function, and physical activity among Frail Older people: a pilot study. J Aging Res 8916274. https://doi.org/10.1155/2018/8916274
van de Bool C, Rutten EPA, van Helvoort A, Franssen FME, Wouters EFM, Schols A (2017) A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J Cachexia Sarcopenia Muscle 8:748–758. https://doi.org/10.1002/jcsm.12219
doi: 10.1002/jcsm.12219
pubmed: 28608438
pmcid: 5659064
Maddocks M, Nolan CM, Man WD, Polkey MI, Hart N, Gao W, Rafferty GF, Moxham J, Higginson IJ (2016) Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial. Lancet Respir Med 4:27–36. https://doi.org/10.1016/S2213-2600(15)00503-2
doi: 10.1016/S2213-2600(15)00503-2
pubmed: 26701362
Vogiatzis I (2011) Strategies of muscle training in very severe COPD patients. Eur Respir J 38:971–975. https://doi.org/10.1183/09031936.00075011
doi: 10.1183/09031936.00075011
pubmed: 21737548
Bhasin S, Jasuja R (2009) Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12:232–240. https://doi.org/10.1097/MCO.0b013e32832a3d79
doi: 10.1097/MCO.0b013e32832a3d79
pubmed: 19357508
pmcid: 2907129
Negro-Vilar A (1999) Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 84:3459–3462. https://doi.org/10.1210/jcem.84.10.6122
doi: 10.1210/jcem.84.10.6122
pubmed: 10522980
Cadilla R, Turnbull P (2006) Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top Med Chem 6:245–270. https://doi.org/10.2174/156802606776173456
doi: 10.2174/156802606776173456
pubmed: 16515480
Schmidt A, Kimmel DB, Bai C, Scafonas A, Rutledge S, Vogel RL, McElwee-Witmer S, Chen F, Nantermet PV, Kasparcova V, Leu C-T, Zhang H-Z, Duggan ME, Gentile MA, Hodor P, Pennypacker B, Masarachia P, Opas EE, Adamski SA, Cusick TE, Wang J, Mitchell HJ, Kim Y, Prueksaritanont T, Perkins JJ, Meissner RS, Hartman GD, Freedman LP, Harada S-i, Ray WJ (2010) Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem 285:17054–17064. https://doi.org/10.1074/jbc.M109.099002
doi: 10.1074/jbc.M109.099002
pubmed: 20356837
pmcid: 2878020
Passey SL, Hansen MJ, Bozinovski S, McDonald CF, Holland AE, Vlahos R (2016) Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease. Pharmacol Ther 166:56–70. https://doi.org/10.1016/j.pharmthera.2016.06.013
doi: 10.1016/j.pharmthera.2016.06.013
pubmed: 27373503
Xu L, Freeman G, Cowling BJ, Schooling CM (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 11:108. https://doi.org/10.1186/1741-7015-11-108
doi: 10.1186/1741-7015-11-108
pubmed: 23597181
pmcid: 3648456
Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2:153–161. https://doi.org/10.1007/s13539-011-0034-6
doi: 10.1007/s13539-011-0034-6
pubmed: 22031847
pmcid: 3177038
Papanicolaou DA, Ather SN, Zhu H, Zhou Y, Lutkiewicz J, Scott BB, Chandler J (2013) A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with Sarcopenia. J Nutr Health Aging 17:533–543. https://doi.org/10.1007/s12603-013-0335-x
doi: 10.1007/s12603-013-0335-x
pubmed: 23732550
Neil D, Clark RV, Magee M, Billiard J, Chan A, Xue Z, Russell A (2018) GSK2881078, a SARM, produces Dose-Dependent increases in lean Mass in Healthy Older men and women. J Clin Endocrinol Metab 103:3215–3224. https://doi.org/10.1210/jc.2017-02644
doi: 10.1210/jc.2017-02644
pubmed: 29982690
Richardson E, Burnell J, Adams HR, Bohannon RW, Bush EN, Campbell M, Chen WH, Coons SJ, Papadopoulos E, Reeve BR, Rooks D, Daniel G (2019) Developing and implementing performance outcome assessments: evidentiary, methodologic, and operational considerations. Ther Innov Regul Sci 53:146–153. https://doi.org/10.1177/2168479018772569
doi: 10.1177/2168479018772569
pubmed: 29739255
Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM (1982) Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed) 284:1607–1608. https://doi.org/10.1136/bmj.284.6329.1607
doi: 10.1136/bmj.284.6329.1607
pubmed: 6805625
Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE (1999) The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 54:213–222. https://doi.org/10.1136/thx.54.3.213
doi: 10.1136/thx.54.3.213
pubmed: 10325896
pmcid: 1745445
Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE (1992) Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 47:1019–1024. https://doi.org/10.1136/thx.47.12.1019
doi: 10.1136/thx.47.12.1019
pubmed: 1494764
pmcid: 1021093
Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40:423–429. https://doi.org/10.1093/ageing/afr051
doi: 10.1093/ageing/afr051
pubmed: 21624928
Ali NA, O’Brien JM Jr., Hoffmann SP, Phillips G, Garland A, Finley JC, Almoosa K, Hejal R, Wolf KM, Lemeshow S, Connors AF Jr., Marsh CB (2008) Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med 178:261–268. https://doi.org/10.1164/rccm.200712-1829OC
doi: 10.1164/rccm.200712-1829OC
pubmed: 18511703
Edgar CJ, Bush EN, Adams HR, Ballinger R, Byrom B, Campbell M, Eremenco S, McDougall F, Papadopoulos E, Slagle AF, Coons SJ (2023) Recommendations on the selection, development, and modification of performance outcome assessments: a good practices Report of an ISPOR Task Force. Value Health 26:959–967. https://doi.org/10.1016/j.jval.2023.05.003
doi: 10.1016/j.jval.2023.05.003
pubmed: 37385712
Cuthbert SC, Goodheart GJ Jr (2007) On the reliability and validity of manual muscle testing: a literature review. Chirop Osteopat 15:4. https://doi.org/10.1186/1746-1340-15-4
doi: 10.1186/1746-1340-15-4
Dobbels F, de Jong C, Drost E, Elberse J, Feridou C, Jacobs L, Rabinovich R, Frei A, Puhan MA, de Boer WI, Williams K, Pinnock H, Troosters T, Karlsson N, Kulich K, Rüdell K (2014) The PROactive innovative conceptual framework on physical activity. Eur Respir J 44:1223. https://doi.org/10.1183/09031936.00004814
doi: 10.1183/09031936.00004814
pubmed: 25034563
pmcid: 4216453
Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, Hopkinson NS, Polkey MI, Vogiatzis I, Tabberer M, Dobbels F, Ivanoff N, de Boer WI, Kulich K, Serra I, Basagaña X, Troosters T, Puhan MA, Karlsson N, Garcia-Aymerich J (2015) The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J 46:988. https://doi.org/10.1183/09031936.00183014
doi: 10.1183/09031936.00183014
pubmed: 26022965
pmcid: 4589432
Wintz MM (1959) Variations in current manual muscle testing. Phys Ther Rev 39:466–475. https://doi.org/10.1093/ptj/39.7.466
doi: 10.1093/ptj/39.7.466
Mohan D, Rossiter HB, Watz H, Fogarty C, Evans RA, Man WD-C, Tabberer M, Beerahee M, Kumar S, Millns H, Thomas S, Tal-Singer R, Russell AJ, Holland MC, Akinseye CU, Neil DR, Polkey MI (2023) Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomized control trial. Thorax 78:258–266. https://doi.org/10.1136/thorax-2021-218360
Apps LD, Mitchell KE, Harrison SL, Sewell L, Williams JE, Young HM, Steiner M, Morgan M, Singh SJ (2013) The development and pilot testing of the self-management programme of activity, coping and education for chronic obstructive pulmonary disease (SPACE for COPD). Int J Chron Obstruct Pulmon Dis 8:317–327. https://doi.org/10.2147/copd.s40414
doi: 10.2147/copd.s40414
pubmed: 23874093
pmcid: 3711650
Holland AE, Spruit MA, Singh SJ (2015) How to carry out a field walking test in chronic respiratory disease. Breathe 11:128–139. https://doi.org/10.1183/20734735.021314
doi: 10.1183/20734735.021314
pubmed: 26306113
pmcid: 4487379
Campo LA, Chilingaryan G, Berg K, Paradis B, Mazer B (2006) Validity and reliability of the modified shuttle walk test in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil 87:918–922. https://doi.org/10.1016/j.apmr.2006.03.005
doi: 10.1016/j.apmr.2006.03.005
pubmed: 16813778
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, van der Enright P, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET (2005) Standardisation of spirometry. Eur Respir J 26:319–338. https://doi.org/10.1183/09031936.05.00034805
doi: 10.1183/09031936.05.00034805
pubmed: 16055882
Uldry C, Janssens JP, de Muralt B, Fitting JW (1997) Sniff nasal inspiratory pressure in patients with chronic obstructive pulmonary disease. Eur Respir J 10:1292. https://doi.org/10.1183/09031936.97.10061292
doi: 10.1183/09031936.97.10061292
pubmed: 9192931
Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, Solomon J, Shields AL (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21:839–842. https://doi.org/10.1016/j.jval.2017.11.014
doi: 10.1016/j.jval.2017.11.014
pubmed: 30005756
Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3:77–101. https://doi.org/10.1191/1478088706qp063oa
doi: 10.1191/1478088706qp063oa
Barreiro E, Gea J (2016) Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease. Chron Respir Dis 13:297–311. https://doi.org/10.1177/1479972316642366
doi: 10.1177/1479972316642366
pubmed: 27056059
pmcid: 5720189
Wüst RCI, Degens H (2007) Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2:289–300
pubmed: 18229567
pmcid: 2695204
Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F (1998) Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158:629–634. https://doi.org/10.1164/ajrccm.158.2.9711023
doi: 10.1164/ajrccm.158.2.9711023
pubmed: 9700144
Kharbanda S, Ramakrishna A, Krishnan S (2015) Prevalence of quadriceps muscle weakness in patients with COPD and its association with disease severity. Int J Chron Obstruct Pulmon Dis 10:1727–1735. https://doi.org/10.2147/COPD.S87791
doi: 10.2147/COPD.S87791
pubmed: 26366065
pmcid: 4562732
Gea J, Casadevall C, Pascual S, Orozco-Levi M, Barreiro E (2016) Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction. J Thorac Dis 8:3379–3400. https://doi.org/10.21037/jtd.2016.11.105
doi: 10.21037/jtd.2016.11.105
pubmed: 28066619
pmcid: 5179410
US Food & Drug Administration (2019) Patient-Focused Drug Development: Methods to Identify What Is Important to Patients Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients-guidance-industry-food-and . Accessed 16 April 2021
Walton MK, Cappelleri JC, Byrom B, Goldsack JC, Eremenco S, Harris D, Potero E, Patel N, Flood E, Daumer M (2020) Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials. Contemp Clin Trials 91:105962. https://doi.org/10.1016/j.cct.2020.105962
doi: 10.1016/j.cct.2020.105962
pubmed: 32087341
Arbuckle R, Carson RT, Maltzahn R, Staunton H (2017) Conducting qualitative ‘exit’ interviews following clinical trials or observational studies: a valuable method for understanding the patient experience, informing measurement strategy, and aiding interpretation of patient-reported outcomes. Paper presented at the ISPOR, May 20-24, 2017, Boston, US
Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, Arbuckle R (2019) An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes 3:16. https://doi.org/10.1186/s41687-019-0100-y
doi: 10.1186/s41687-019-0100-y
pubmed: 30830492
pmcid: 6399361
Gater A, Marshall C, Grant L, Wells J (2017) The Use of Qualitative (Exit) Interviews in Clinical Trials: Value, Implementation and Key Considerations. Paper presented at the ISPOR, May 20-24, 2017, Boston, US
Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB (2017) Understanding the patient experience with carcinoid syndrome: exit interviews from a Randomized, Placebo-controlled study of Telotristat Ethyl. Clin Ther 39:2158–2168. https://doi.org/10.1016/j.clinthera.2017.09.013
doi: 10.1016/j.clinthera.2017.09.013
pubmed: 29074312
Taylor SW, Goshe BM, Marquez SM, Safren SA, O’Cleirigh C (2018) Evaluating a novel intervention to reduce trauma symptoms and sexual risk taking: qualitative exit interviews with sexual minority men with childhood sexual abuse. Psychol Health Med 23:454–464. https://doi.org/10.1080/13548506.2017.1348609
doi: 10.1080/13548506.2017.1348609
pubmed: 28697624
Wells JR, Gater A, Marshall C, Tritton T, Vashi P, Kessabi S (2019) Exploring the impact of infusion frequency in Hemophilia A: exit interviews with patients participating in BAY 94-9027 Extension studies (PROTECT VIII). Patient 12:611–619. https://doi.org/10.1007/s40271-019-00374-x
doi: 10.1007/s40271-019-00374-x
pubmed: 31313270
pmcid: 6884429
Williamson N, Tabberer M, Wells J, Gibbons E, Tatlock S (2020) Application and value of qualitative in-trial or ‘exit’ interviews to generate supplementary evidence regarding patients’ trial, treatment and disease experiences: examples from multiple disease areas. Paper presented at the ISOQOL Symposium, 21–24 October, 2020, Prague, Czech Republic